Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
Apollo Endosurgery, Inc. (APEN)
|
Add to portfolio |
|
|
|
| Price: |
$8.33
| | Metrics |
| OS: |
40.7
|
M
| |
-75
|
% ROE
|
| Market cap: |
$339
|
M
| |
-99
|
% ROIC
|
|
Net cash:
|
$21.4
|
M
| |
$0.53
|
per share
|
|
EV:
|
$318
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($21.1)
|
M
| |
|
|
|
EBIT
|
($24.0)
|
M
| |
|
|
| EPS |
($1.04)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-05-17 | Dec-31-16 |
| Revenues | 63.0 | 42.0 | 50.7 | 60.9 | 60.9 | 64.3 | 26.0 | 64.7 |
| Revenue growth | 49.8% | -17.1% | -16.7% | -5.4% | 134.0% | -0.5% | | -4.6% |
| Cost of goods sold | 28.0 | 19.8 | 25.0 | 27.7 | 27.7 | 24.6 | 0.0 | 25.3 |
| Gross profit | 35.0 | 22.2 | 25.7 | 33.2 | 33.2 | 39.7 | 26.0 | 39.4 |
| Gross margin | 55.5% | 52.9% | 50.6% | 54.5% | 54.5% | 61.8% | 100.0% | 60.9% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 24.3 | 17.4 | 28.7 | 32.8 | 32.8 | 32.9 | 32.9 | 31.5 |
| Research and development | 9.5 | 7.7 | 10.4 | 12.2 | 12.2 | 8.3 | 8.3 | 7.8 |
| General and administrative | 18.4 | 11.1 | 13.6 | 13.4 | 13.4 | 13.7 | | 13.6 |
| EBITA | -17.3 | -13.8 | -27.0 | -25.2 | -33.0 | -15.2 | -15.2 | -13.6 |
| EBITA margin | -27.5% | -32.9% | -53.3% | -41.5% | -54.3% | -23.6% | -58.4% | -21.0% |
| Amortization of intangibles | 1.9 | 1.9 | 2.1 | 7.1 | 7.1 | 7.2 | 7.2 | 7.2 |
| EBIT | -19.2 | -15.8 | -29.1 | -32.3 | -40.1 | -22.4 | -22.4 | -20.8 |
| EBIT margin | -30.5% | -37.6% | -57.4% | -53.1% | -65.9% | -34.9% | -86.3% | -32.1% |
| Pre-tax income | -24.5 | -22.5 | -27.2 | -45.6 | -45.6 | -27.0 | -27.0 | -40.8 |
| Income taxes | 0.2 | 0.1 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 |
| Tax rate | | | | | | | | |
| Net income | -24.7 | -22.6 | -27.4 | -45.8 | -45.8 | -27.3 | -27.3 | -41.2 |
| Net margin | -39.2% | -53.8% | -54.1% | -75.2% | -75.2% | -42.4% | -104.9% | -63.7% |
| |
| Diluted EPS | ($0.82) | ($0.99) | ($1.27) | ($2.31) | ($2.31) | ($2.01) | ($2.01) | ($105.69) |
| Shares outstanding (diluted) | 30.2 | 22.8 | 21.5 | 19.8 | 19.8 | 13.6 | 13.6 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|